Project Staff
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Dr. Lamis Yehia is a leader in the genetic basis, clinical phenotype and pathophysiology of PTEN hamartoma tumor syndrome (PHTS). She completed her doctoral training at Case Western Reserve University after being awarded an International Fulbright Scholarship. During her thesis, Dr. Yehia identified novel genes that predispose to cancer in Cowden and related overgrowth syndromes. Dr. Yehia completed her post-doctoral work in the Genomic Medicine Institute at Cleveland Clinic under the mentorship of Dr. Charis Eng, where she led translational efforts to understand mechanisms underlying the natural history and phenotype heterogeneity within overgrowth syndromes. Her collective work includes more than 40 original research publications including as lead author of authoritative clinical resources on the PTEN hamartoma tumor syndrome such as GeneReviews. Dr. Yehia is currently an investigator at the Cleveland Clinic Neurological Institute where she continues to pursue understanding the determinants of the neurodevelopmental in addition to cancer phenotype of PTEN-mediated disorders.
P9. Discovery of novel genetic drivers of Cowden Syndrome using genome-wide CRISPR/Cas9 screening
Thursday, March 5, 2026
11:28 AM - 11:35 AM MST